TABLE 1.

Patient demographics, voriconazole levels, indications, and outcomes for patients with lower serum concentrations

Patient no.Age range (yr)GenderaWt (kg)ComorbiditybFungal diseasecLevel (μg/ml)ProgressionVoriconazole dose changed as result of levelSurvival
136-40F56Lung TxIA1.0YesYesNo
236-40F43Kidney TxIA0.3, 0.9YesYesYes
341-45M51BMTIA1.5NoNoNo
436-40M64Lung TxIA0.9, 1.2NoYesYes
556-60M64CLLIA1.2YesNoNo
646-50M43BMTIA0.7NoNoYes
726-30F99Hodgkin's diseaseIA0.3YesNoNo
831-35F41BMTIA1.8YesNoNo
936-40F58Lung TxIA0.4NoYesYes
1036-40M60ALL, BMTIA0.2YesNoNo
1151-55M105Renal TxIA0.8, 1.5YesYesYes
1241-55M82Renal TxIA<0.2, <0.2YesYesYes
1336-40M137Liver TxIA0.7, 4.4 (peak), 4.8 (trough)YesYesNo
1416-20F48Lung Tx Scedosporium 0.8, 0.7, 2.9YesYesYes
1551-55M175Liver TxBlastomycosis<0.2, 0.3, 2.4YesYesYes
1661-65M78Lung TxIA0.6, 1.2, 1.5YesYesYes
1766-70M100Liver TxIA, blastomycosis0.9, 2.4, 2.3YesYesNo
1856F59Heart TxIA2.8NoNoYes
1939F46Heart TxIA3.9NoNoYes
2036M80Renal Tx Candida 2.9NoNoYes
2152M90IA3.5NoNoYes
2232F48Lung TxIA2.2NoNoYes
2340M58LiverIA4.0NoNoYes
2440F63BMTIA1.6NoNoYes
250.8F61Renal TxIA0.8YesYesYes
2664M64AMLIA13.2NoYesYes
2746F46Unknown Cryptococcus 2.5NoNoYes
2841F45Renal TxIA2.9NoNoYes
  • a F, female; M, male.

  • b Tx, transplant; BMT, bone marrow transplant; CLL, chronic lymphocytic leukemia; ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia.

  • c IA, invasive aspergillosis.